


Rineterkib hydrochloride

Cat. No.:	HY-114491A
CAS No.:	1715025-34-5
Molecular Formula:	C ₂₆ H ₂₇ BrF ₃ N ₅ O ₂ .xClH
Target:	Raf; ERK
Pathway:	MAPK/ERK Pathway; Stem Cell/Wnt
Storage:	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 220 mg/mL (Need ultrasonic)
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 5.5 mg/mL (Infinity mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 5.5 mg/mL (Infinity mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 5.5 mg/mL (Infinity mM); Clear solution

BIOLOGICAL ACTIVITY

Description	Rineterkib hydrochloride (compound B) is an orally active RAF and ERK1/2 inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovarian cancer ^[1] .								
In Vivo	<p>ERK-IN-1 (compound B) (50, 75 mg/kg, p.o., qd/q2d, 27 days) treatment significantly reduces the tumor volume in the Calu-6 human NSCLC subcutaneous tumor xenograft model in mice^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Calu-6 NSCLC xenograft tumor models in mice^[1].</td> </tr> <tr> <td>Dosage:</td> <td>50, 75 mg/kg.</td> </tr> <tr> <td>Administration:</td> <td>Orally either daily (qd) or every other day (q2d) for 27 days.</td> </tr> <tr> <td>Result:</td> <td>Significantly reduced the tumor volume.</td> </tr> </table>	Animal Model:	Calu-6 NSCLC xenograft tumor models in mice ^[1] .	Dosage:	50, 75 mg/kg.	Administration:	Orally either daily (qd) or every other day (q2d) for 27 days.	Result:	Significantly reduced the tumor volume.
Animal Model:	Calu-6 NSCLC xenograft tumor models in mice ^[1] .								
Dosage:	50, 75 mg/kg.								
Administration:	Orally either daily (qd) or every other day (q2d) for 27 days.								
Result:	Significantly reduced the tumor volume.								

REFERENCES

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA